TARDBP and amyotrophic lateral sclerosis: To provide a proof-of-concept examination, we developed “TDP-43 PROTAC” as a novel therapeutic strategy for reducing the C-TDP-43 cytotoxicity in ALS and other TDP-43 proteinopathy (Fig. 1A).